Abatacept in Individuals Who aRe Considered At Risk of Developing Inflammatory Arthritis

PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped The CI terminated ARCADIA early due to a number of reasons. These include the difficulty in recruiting and being placed on pause during the COVID pandemic, plus limited staffing at that time \& the need to considerably amend the eCRF MACRO system

Conditions

Inflammatory Arthritis

Interventions

DRUG: Orencia 125 MG Per 1 ML Prefilled Syringe

Sponsor

University of Leeds